The race to protect against the deadly Nipah virus is on, and the world is taking notice. With no approved countermeasures currently available, the Coalition for Epidemic Preparedness Innovations (CEPI) is leading the charge with a $150 million R&D portfolio. This comprehensive approach spans the entire preparedness chain, from countermeasure development and manufacturing to anticipating and preparing for a potential Nipah-like 'Disease X' from the same paramyxovirus family. One of the most advanced vaccine candidates, developed in partnership with the University of Oxford and Serum Institute of India, is already in Phase II trials in Bangladesh, a country where the virus poses a significant threat.
The story of Nipah's deadly impact begins with a seemingly harmless fruit juice, a popular drink in rural Bangladesh. Dr. K. Zaman, a leading researcher at ICDDR,b, explains how raw date juice, enjoyed by many, can be contaminated by bats carrying the Nipah virus. This contamination leads to infection, and the virus's high death rate of up to 75% makes it one of the world's most lethal viral pathogens. The potential for mutation and spread to other regions further emphasizes the urgency of developing a protective vaccine.
The CEPI-funded partnership with the University of Oxford has resulted in a groundbreaking vaccine candidate, ChAdOx1 NipahB, which began mid-stage clinical trials in Bangladesh in late 2025. Dr. Zaman's expertise in overseeing numerous clinical trials positions him to lead this trial, aiming to generate valuable knowledge on the vaccine's potential to save lives in Bangladesh and beyond. The vaccine's development is not limited to Bangladesh; the virus's natural hosts, fruit bats, are found across regions with over two billion inhabitants, increasing the risk of spillover as human activity encroaches on their habitats.
Rick Jarman, the Nipah program lead at CEPI, highlights the concern over the virus's susceptibility to a wide range of domestic and farm animals. Nipah can infect humans through contaminated food and direct contact with infected animals, and each spillover event increases the risk of mutation and potential transmissibility. CEPI's $150 million portfolio includes two vaccine candidates and a monoclonal antibody, all aimed at strengthening global preparedness.
The collaboration with Serum Institute of India is a key part of this preparedness. Serum is not just a manufacturing partner but also a world-class vaccine developer with regulatory experience and a strong relationship with the Indian government. This partnership enables the production of the ChAdOx1 NipahB vaccine candidate for the Bangladesh trials and aims to create an investigational reserve of up to 100,000 doses, ready for deployment in an outbreak. Jarman emphasizes that this investigational reserve is CEPI's top priority for the next year or two, allowing for the launch of emergency trials and the potential for rapid licensure.
The development of a Nipah monoclonal antibody, MBP1F5, led by ServareGMP, is another crucial aspect of the preparedness strategy. This antibody, which could provide immediate protection, is set to begin early to mid-stage trials in a Nipah-affected country in 2026. When used in conjunction with vaccines, these antibodies could form a potent protective shield, potentially constraining an outbreak's impact. Investing in a range of novel technologies and modalities increases the likelihood of successful countermeasure development and validates the technology for future Disease X threats.
The collaboration with Serum and the development of the Nipah mAb are part of a broader strategy to strengthen global preparedness against not only Nipah virus but the entire paramyxovirus viral family. If a future paramyxovirus Disease X emerges, platforms like ChAdOx could be quickly adapted to create new vaccines, leveraging the scientific knowledge and data generated from Nipah R&D. Combined with regional manufacturing capabilities and expertise, this approach could accelerate the development of life-saving vaccines against emerging paramyxoviruses with epidemic or pandemic potential, supporting CEPI's 100 Days Mission.
